Sarep­ta adds black box warn­ing to its Duchenne treat­ment, cuts 500 work­ers

Sarep­ta Ther­a­peu­tics, dogged by safe­ty con­cerns over its con­tro­ver­sial Duchenne mus­cu­lar dy­s­tro­phy treat­ment, is cut­ting costs and lay­ing off hun­dreds of work­ers as part of …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER